Diabetes and Osteoporosis: Part II, Clinical Management

G Isanne Schacter; William D Leslie

doi:10.1016/j.ecl.2021.03.006

Diabetes and Osteoporosis: Part II, Clinical Management

Endocrinol Metab Clin North Am. 2021 Jun;50(2):287-297. doi: 10.1016/j.ecl.2021.03.006. Epub 2021 Apr 28.

Authors

G Isanne Schacter¹, William D Leslie²

Affiliations

¹ Department of Medicine, Rady Faculty of Health Sciences, University of Manitoba, GF-335, 820 Sherbrook Street, Winnipeg, Manitoba R3A 1R9, Canada.
² Department of Medicine, Rady Faculty of Health Sciences, University of Manitoba, C5121, 409 Tache Avenue, Winnipeg, Manitoba R2H 2A6, Canada. Electronic address: bleslie@sbgh.mb.ca.

PMID: 34023044
DOI: 10.1016/j.ecl.2021.03.006

Abstract

Diabetes-induced osteoporosis is characterized by an increase in fracture risk. FRAX, the most widely used tool, underestimates the risk of fracture in both type 1 and type 2 diabetes. Specific adjustments to FRAX can help to better identify patients with diabetes at increased risk of fracture and select those at high fracture risk for treatment. Although clinical trial data are limited, the available evidence indicates that the presence of diabetes does not alter antiosteoporotic treatment response in patients with diabetes.

Keywords: Bone; Bone mineral density; Diabetes; Dual-energy x-ray absorptiometry; Fracture; Osteoporosis.

Publication types

Review

MeSH terms

Bone Density
Diabetes Mellitus, Type 1* / complications
Diabetes Mellitus, Type 1* / therapy
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / therapy
Humans
Osteoporosis* / etiology
Osteoporosis* / therapy
Osteoporotic Fractures / epidemiology
Risk Assessment